(Q34301038)

1 August 2017

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

pancreatic adenocarcinoma

1 August 2017

1 reference

1 reference

based on heuristic

inferred from title

author

ESMO Guidelines Working Group

5

object named as

ESMO Guidelines Working Group

1 reference

1 August 2017

T Seufferlein

1

1 reference

1 August 2017

J B Bachet

2

1 reference

1 August 2017

E Van Cutsem

3

1 reference

1 August 2017

P Rougier

4

1 reference

1 August 2017

language of work or name

1 reference

1 October 2012

1 reference

1 August 2017

1 reference

1 August 2017

23 Suppl 7

1 reference

1 August 2017

vii33-40

1 reference

Estimates of cancer incidence and mortality in Europe in 2008.

1 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

European cancer mortality predictions for the year 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Body mass index and risk, age of onset, and survival in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Redefining the R1 resection in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Redefining resection margin status in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS224

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS224

1 reference

1 August 2017

1 reference